Posts by camerontucker
Fresh vs Cryopreserved Leukopaks for T Cell Expansion and CAR T Manufacturing
Why the fresh vs cryo decision matters Most CAR T processes are built around predictable inputs. When those inputs shift, it becomes harder to hit target yields, expansion timing, and manufacturing release criteria. Fresh and cryopreserved leukopaks differ in: logistics and scheduling flexibility post processing recovery and expansion behavior sensitivity to handling variables lot to…
For More InformationArmored CAR T
Strengthening T Cells for the Toughest Tumors CAR T therapy changed what is possible in blood cancers. But solid tumors remain one of the toughest frontiers in oncology. Not because we do not know what to target.Because the tumor environment fights back. Solid tumors suppress immune activity, block infiltration, and exhaust T cells before they…
For More InformationBest CD34+ Cell Suppliers for 2026: Comparing Bone Marrow, Cord Blood, and Mobilized Sources
Introduction CD34+ hematopoietic stem and progenitor cells are critical to cell therapy development, gene editing workflows, and translational immunology research. Whether sourced from bone marrow, mobilized peripheral blood, or cord blood, CD34 cell quality and documentation directly influence downstream expansion, differentiation, and functional outcomes. In 2026, research teams are evaluating suppliers based not only on…
For More InformationBest Mobilized Leukopak Suppliers for 2026: G-CSF vs. Plerixafor Compared
Introduction Mobilized leukopaks are essential starting material for advanced cell therapies, immune research, and manufacturing optimization. By mobilizing hematopoietic stem and progenitor cells (HSPCs) from the bone marrow into the bloodstream using agents like G-CSF or plerixafor, researchers can isolate higher yields of CD34+ and target immune cells for CAR T, NK, and other immunotherapy…
For More InformationOptimizing PBMC Viability and Recovery: Updated Best Practices for 2026
In biomedical research, the viability and recovery of peripheral blood mononuclear cells (PBMCs) determine the reliability of downstream results. Over the past few years, advances in donor screening, cryopreservation, and logistics have dramatically improved the consistency of primary immune cell performance. Yet, small variables—temperature shifts, prolonged DMSO exposure, or donor differences—still account for major discrepancies…
For More InformationMeet CGT Global’s Scientific Team: Sophia Johnson Associate Director of Logistic Operations
For cell procurement and delivery operations to run smoothly, countless moving parts must align. From understanding the needs of a research project to scheduling donors, fulfilling orders, and ensuring precise delivery, every step must fit together seamlessly. So, who keeps everything ticking like a perfectly timed clock? Meet Sophia Johnson, Associate Director of Logistic Operations at CGT Global. Sophia has been with…
For More InformationScaling Humanized Immune System Mouse Models: Optimize Your CD34+ Engraftment with High Quality Cells
Table of contents Key Takeaways CD34+ humanized mice enable better predictions for therapies, reducing the translational gap between humans and mice. High-quality CD34+ cells from CGT Global enhance engraftment success rates for HIS mice in preclinical studies. Cell viability, purity, and accurate counts are crucial for consistent and predictive data from these models. Ordering bulk…
For More InformationTop PBMC Suppliers for 2026: Fresh, Cryopreserved, and GMP-Grade Options Compared
Introduction Peripheral Blood Mononuclear Cells (PBMCs) are foundational to immunology, oncology, and cell therapy research. Whether they are used for functional assays, vaccine development, or discovery-stage therapeutic studies, PBMC quality directly impacts data accuracy and reproducibility. In 2026, researchers expect more than just availability. They look for documented donor screening, consistent viability, and responsive support.…
For More InformationBest Leukopak Suppliers for Cell Therapy in 2026: Pricing, Quality, and Turnaround Compared
Introduction When it comes to sourcing leukopaks for cell therapy or research, product quality is only half the story. Procurement delays, unanswered inquiries, and limited visibility can stall entire workflows. In 2026, speed and communication matter just as much as purity and yield. To help researchers, process developers, and procurement teams choose confidently, we reviewed…
For More InformationThe Donors Powering Breakthroughs in Maternal and Infant Health
Become a Donor 📞 Call or Text (916) 350-0714 Every great discovery begins with a volunteer. At CGT Global, maternal blood donors are at the heart of pregnancy and infant health research. Their contributions help scientists understand how life begins, how the body adapts during pregnancy, and how to prevent complications that still threaten mothers and…
For More Information